WLDBF yields 217.39% · PFE yields 6.13%● Live data
📍 WLDBF pulled ahead of the other in Year 1
Combined, WLDBF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WLDBF + PFE for your $10,000?
WildBrain Ltd. develops, produces, and distributes films and television programs worldwide. The company operates through two segments, Content Business and Canadian Television Broadcasting. It focuses on children and family content, including animated series; and provides production services, as well as operates children's channels on YouTube. The company also licenses initial broadcasting rights of new proprietary series or pre-sells shows that are in development to individual broadcasters, streaming services, and other media platforms; and re-licenses rights of existing series in the library or packages of programs of its own proprietary titles, as well as third-party produced titles. In addition, it holds broadcast licenses for Family Channel, Family Jr., Télémagino, and Family CHRGD television channels; and operates as entertainment, sport, and brand licensing agency for the company's own and third party brands. Further, the company licenses its brands, such as Peanuts, Strawberry Shortcake, Chip and Potato, Teletubbies, Yo Gabba Gabba!, Caillou, Johnny Test, In the Night Garden, Twirlywoos, Mattel on Bob the Builder, Fireman Sam, Little People, and Polly Pocket, as well as music publishing and retransmission rights, and live tours. It offers its films and television programs for streaming services; and conventional and specialty terrestrial and cable/satellite television broadcasters, as well as for other media platforms and digital providers. The company was formerly known as DHX Media Ltd. and changed its name to WildBrain Ltd. in December 2019. WildBrain Ltd. was incorporated in 2004 and is headquartered in Halifax, Canada.
Full WLDBF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.